MLTX - Moonlake Immunotherapeutics
NYSE * Health Care * Biotechnology
$18.02
$-0.12 (-0.66%)
About Moonlake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
MLTX Key Statistics
Market Cap
$1.30B
P/B Ratio
4.34
EPS
$-3.53
Employees
130
How MLTX Compares to Peers
P/E Rank
N/A
of 5
Margin Rank
N/A
of 5
Growth Rank
N/A
of 5
Size Rank
#6
of 6
Moonlake Immunotherapeutics Company Information
- Headquarters
- Massachusetts; U.S.A
- Website
- www.moonlaketx.com
- Sector
- Health Care
- Industry
- Biotechnology